Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II Study of Neoadjuvant Chemotherapy plus Autologous Cytokine-Induced Killer Cell Therapy in ER-negative/HER2-negative Breast Cancer
KCT0008408Phase 2Not yet recruiting
- Sponsor
- Regenerative Medicine Foundation
- Start
- Apr 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous cytokine-induced killer cells in breast cancer, triple-negative breast cancer (TNBC), sponsored by Regenerative Medicine Foundation. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on KCT0008408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008408.